Tarsus Pharmaceuticals TARS Holds Steady Near Support as Market Watches Key Levels EUChina Trade Relations Face Critical Juncture as Brussels Reassesses Strategy KURA Q1 2026 Earnings Wider than Expected Loss Pressures Shares Treasury Yield Surge Challenges RiskFree Status Opens Opportunities in Intermediate BBB and High Yield Bonds